These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


132 related items for PubMed ID: 20347331

  • 1. Low levels of extraneous agents in vaccine starting materials.
    Rouby JC.
    Biologicals; 2010 May; 38(3):354-7. PubMed ID: 20347331
    [Abstract] [Full Text] [Related]

  • 2. Tracing and control of raw materials sourcing for vaccine manufacturers.
    Faretra Peysson L.
    Biologicals; 2010 May; 38(3):352-3. PubMed ID: 20335052
    [Abstract] [Full Text] [Related]

  • 3. Extraneous agents testing for substrates of avian origin and viral vaccines for poultry: current provisions and proposals for future approaches.
    Jungbäck C, Motitschke A.
    Biologicals; 2010 May; 38(3):362-5. PubMed ID: 20335053
    [Abstract] [Full Text] [Related]

  • 4. Risk reduction in biotherapeutic products.
    Ill CR, Dehghani H.
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):296-304. PubMed ID: 19333875
    [Abstract] [Full Text] [Related]

  • 5. Viral safety and extraneous agents testing for veterinary vaccines: rationale for requirements, the European approach.
    Bruckner L.
    Biologicals; 2010 May; 38(3):338-9. PubMed ID: 20335051
    [Abstract] [Full Text] [Related]

  • 6. Current challenges in viral safety and extraneous agent testing.
    Mackay D, Kriz N.
    Biologicals; 2010 May; 38(3):335-7. PubMed ID: 20338787
    [Abstract] [Full Text] [Related]

  • 7. Comparison of requirements in the European Union and United States of America for pre-clinical viral safety testing of veterinary vaccines.
    Sheridan S, Coughlin J.
    Biologicals; 2010 May; 38(3):340-5. PubMed ID: 20400329
    [Abstract] [Full Text] [Related]

  • 8. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M.
    ALTEX; 2001 May; 18 Suppl 1():13-47. PubMed ID: 11854853
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Organic solvents in the pharmaceutical industry.
    Grodowska K, Parczewski A.
    Acta Pol Pharm; 2010 May; 67(1):3-12. PubMed ID: 20210074
    [Abstract] [Full Text] [Related]

  • 13. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW, Golker CF, Stadler P.
    Dev Biol Stand; 1996 May; 88():257-64. PubMed ID: 9119148
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anticancer Drug Development: The Way Forward.
    Connors T.
    Oncologist; 1996 May; 1(3):180-181. PubMed ID: 10387985
    [Abstract] [Full Text] [Related]

  • 17. Ensuring the quality, potency and safety of vaccines during preclinical development.
    Lebron JA, Wolf JJ, Kaplanski CV, Ledwith BJ.
    Expert Rev Vaccines; 2005 Dec; 4(6):855-66. PubMed ID: 16372881
    [Abstract] [Full Text] [Related]

  • 18. Adventitious agents from animal-derived raw materials--a method of risk assessment.
    Foster LG.
    Dev Biol Stand; 1996 Dec; 88():283-90. PubMed ID: 9119152
    [Abstract] [Full Text] [Related]

  • 19. Who Expert Committee on Biological Standardization.
    World Health Organization.
    World Health Organ Tech Rep Ser; 2004 Dec; 926():1-109. PubMed ID: 15918537
    [Abstract] [Full Text] [Related]

  • 20. Technical Report No. 38. Manufacturing chromatography systems postapproval changes (ChromPAC): chemistry, manufacturing, and controls documentation.
    PDA Manufacturing Chromatography Systems PAC Taskforce.
    PDA J Pharm Sci Technol; 2006 Mar; 60(1 Suppl TR38):1-29. PubMed ID: 16696189
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.